Skip to content

A prospective multicenter cohort study on the construction of a precise diagnosis and treatment system for prostate cancer based on liquid biopsy technology

A prospective multicenter cohort study on the construction of a precise diagnosis and treatment system for prostate cancer based on liquid biopsy technology

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300070137
Enrollment
Unknown
Registered
2023-04-03
Start date
2023-04-03
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Interventions

Group of suspected prostate cancer:None

Sponsors

Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Age equal to or greater than 18 years and less than 90 years at the time of signing informed consent. 2. Patients who are candidates for prostate puncture because of elevated PSA, or positive digital rectal examination, or imaging findings suggestive of suspected prostate cancer; Or patients with pathologic diagnosis of prostate cancer by puncture / surgery. 3. Expected survival > 12 months 4. ECoG score 0-2 points 5. Patient consent and ability to follow the planned study visit, provide blood, urine and surgical samples for the specified period of treatment, may provide clinical information and cooperate with other study steps 6. Patients had normal organ function with WBC = 3000 / mm3 or absolute neutrophil count = 1500 / mm3 and AST and ALT below 1.5 ULN.

Exclusion criteria

Exclusion criteria: 1. The investigator judged that the patient had other serious illnesses that could affect follow-up and short-term survival, and any medical cause that showed a significant risk of death during the 1-year study period 2. Had any other malignancy within 3 years prior to enrollment 3. Clinical information required for the study was not available. 4. Situations in which enrollment was not considered appropriate by the other investigators

Design outcomes

Primary

MeasureTime frame
Multiomics features of blood;Multiomics features of urine;Multiomics features of histopathology;Features of clinicopathological information;

Countries

CHINA

Contacts

Public ContactYi Cai

Xiangya Hospital of Central South University, No. 87 Xiangya Road, Kaifu District, Changsha, Hunan Province

cai-yi@csu.edu.cn+86 13637310713

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026